The HER-2/neu (c-erbB-2) oncogene codes for a 185-kD transmembrane tyrosine kinase. Its presence has been reported in numerous tumors of various organ sites, including the cervix. It has been reported that expression is pronounced in some patients with stage III and IV cervical disease (10) . Tissue levels have been examined by immunohistochemical means (IHC), using the same techniques as for breast cancer. It has been reported that there was no survival difference between positive and negative expression, nor was it of any value as a predictor of recurrence (11) . Yet these authors state that 22% of the patients expressed the oncogene, but that it is a rare occurrence in cervical cancer; this is almost one in four patients. Another technique of evaluating tissue HER-2/neu is fluorescent in situ hybridization (FISH) . With use of this technique, it was found that 8.7% of invasive cervical cancer tumors expressed the oncogene. This suggested to these authors that this technique was sensitive and feasible to evaluate these patients (12) . Another study found that the FISH technique was more sensitive that even southern blot analysis, 37% positive as compared to 14% (13) . When this type of evaluation was expanded to early cervical cancer (stage I or II), only 12 of 136 patients had positive results, suggesting that amplification is minimal in early cervical cancer (14) .
Because the tissue expression can only be realistically evaluated once, at biopsy or surgery, attempts to monitor this oncogene in serum were initiated. Serum levels were found to be elevated in advanced breast, lung, ovarian, prostate gland, and gastric cancer, suggesting a possible use of the serum expression of this oncogene as a tumor marker (15) . This was further supported by expanded studies into other gynecologic cancer as well (16) . Likewise in receptor positive breast cancer patients undergoing hormonal therapy, it was noted that survival was shorter in the patients with elevated HER-2/neu, with a lessened response to treatment (17) . When this study was expanded to 211 patients with advanced breast cancer undergoing chemotherapy, it was found that in the serum the HER-2/neu oncogene expression was a good predictive indicator of disease-free survival, but not overall survival. In addition, it was a better predictor of the risk of recurrence than was nodal involvement or receptor status (18) . One early study attempted to compare tissue levels to serum levels in patients with ovarian carcinoma. Seventeen of 45 patients illustrated an IHC overexpression of tissue HER-2/neu, and five of these patients had elevated serum lev-els as well. This led to a specificity calculation of 93% correlation (19) . Another similar study found that from 57 patients with ovarian cancer, eight overexpressed the oncogene, and four had elevated serum levels, a 50% correlation. This suggested that circulating HER-2/neu might act as a diagnostic tool in ovarian cancer as well (20) .
The significance of the circulating form of HER-2/neu relates to its domains. This intact oncogene, (p185), has three specific domains: intracellular, transmembrane, and the extracellular p105 fraction. It is the p105 fraction that is shed into the circulation and is the basis of the serum assay (21) . Elevated p105 correlated to a poor prognosis in terms of the patient's survival, especially in advanced disease. This suggested elevated serum p105 in patients with ovarian cancer patients had a poor clinical outcome (22) . In a recent study (23) , serum levels of HER-2/neu were elevated in 5.5% of benign ovarian masses, 16.7% of borderline tumors, and 38% of malignant ovarian tumors, but this oncogene was not useful even with corresponding CA 125 to differentiate between benign and actual tumor patients. It has also been suggested that HER-2/neu oncogenicity in epithelial tumors was related to the oncogene's ability to act as a receptor for the stromal-derived growth factors (24) . In patients with ovarian cancer being followed after second-line chemotherapy, no significant response in serum HER-2/neu was found in either survival or treatment response (25) . In tissue samples from patients with ovarian cancer following platin-based chemotherapy, expression of the oncogene indicated a significant prognostic value for response to chemotherapy and survival. This suggested that HER-2/neu had a prognostic value after treatment, and low tissue expression in ovarian cancer correlated with a good outcome at second look (26) .
There has been no attempt as of yet to evaluate serum HER-2/neu in those patients with cervical cancer comparing serum levels of HER-2/neu to uPA to evaluate if upregulation of uPA is occurring as was reported from in vitro experiments. To our knowledge, this study is the first known evaluation of this possible relationship in the serum of patients with cervical cancer.
METHODS AND MATERIALS

Patients
All patients with cervical cancer participating in this study were seen at the Southwest Cancer Center of Texas Tech Health Sciences Center, Division of Gynecologic Oncology. Control patient serum (n = 111) was obtained from the gynecology clinic from premenopausal women not taking oral contraceptives. All volunteer blood samples were collected following signed informed consent; this is an IRB approved study. The patients with cervical cancer all underwent a biopsy to pathologically verify the type and stage of cervical disease. Thirty-two total patients with cervical cancer were entered into the study. The patients were divided into early (stage I or II, n = 23) or advanced (stage III or IV, n = 9) for statistical purposes. These patients with verified cervical cancer (32) then had a serum sample collected just before initiation of treatment for baseline evaluation of the variables.
Analysis
A monoclonal antibody-based sandwich ELISA using kits obtained from Oncogene Science Diagnostics (Cambridge, MA) determined the baseline serum levels of both the p105 extracellular domain of HER-2/neu and uPA.
Statistics
Data were analyzed by several methods using the "INSTAT" program from GRAPHPAD (San Diego, CA). When comparing cervical cancer patients to the controls, the nonparametric Mann-Whitney t test was used. Relationships between variables within controls and cervical cancer patients were determined by correlation analysis, the parametric Pearson's correlation for the controls, and the nonparametric Spearman's rank correlation for the patients with cervical cancer. All significance levels were at a p value less than 0.05 for two-tailed tests.
RESULTS
In the pre-treatment period, neither the circulating uPA or HER-2/neu were significantly different from each other in controls versus patients (Tables 1 and 2) .
When the resultant data were evaluated according to stage of disease, either early or advanced, again no significant difference was found compared to the controls. When the patients with advanced cervical cancer were compared to the patients with early cervical cancer, there were no significant differences between any variable ( Table 2) , although the increase in uPA in the advanced stage patients approached significance even with the small number of patients (9) . In the control patients, serum uPA was not significantly correlated with HER-2/neu. In the 32 patients with cervical cancer, both early and advanced, there was no correlation between uPA and HER-2/neu either. When broken out by stage, a significant correlation was observed for the early stage patients (p = 0.02), which was not seen in the advanced stage disease (p = 0.7).
DISCUSSION
Ovarian epithelial cell malignancy is the leading cause of mortality in gynecologic cancer. A characteristic of this tumor is the intra-abdominal metastases of shed surface tumor cells and subsequent implantation, which is known to occur via cell adhesion and extracellular matrix proteolysis (27) . This tissue remodeling is dependent upon urokinase promotion of tumor cell invasion (28) .
The receptor for uPA is located on the cell membrane, has a soluble form in the circulation, and allows both binding and activation of uPA. This in turn leads to the conversion of plasminogen to plasmin, and the resultant proteolytic activity associated with plasmin. This increase in plasmin can affect the spread of cancer in several ways. The plasmin-directed dissemination of the cancer cells can occur either by the direct promotion of cell migration, or by aiding in the breakdown of the extracellular matrix. This is mediated in part by the activation of tyrosine kinase (29) . In the normal physiologic process, a major function of the intact p185 fraction of the HER-2/neu proto-oncogene is to activate tyrosine kinase activity (30) . Therefore a direct link between uPA, its receptor, and HER-2/neu may exist from this tyrosine kinase relationship. It has previously been reported that uPA upregulates HER-2/neu in lung cancer cells in vitro (1) . A recent report on this possible relationship of the urokinase plasminogen activator to HER-2/neu in vivo has appeared. They observed that the circulating p105 fraction of the HER-2/neu protooncogene in serum does not upregulate circulating uPA in those patients with advanced stage non-small-cell lung cancer (31) . Tables 1 and 2 , cervical cancer does not induce any significant increase in either circulating uPA or HER-2/neu when compared to normal age-matched women.
As is evidenced in both
Few papers have addressed the possible role or function of the p105 fraction of HER-2/neu in the blood of patients with gynecologic cancer. Cheung and colleagues (23) described elevated serum levels in 38% of patients with ovarian cancer, which is similar to the expression rate seen in malignant ovarian tissue. They did not observe these patients after treatment, however. Serial blood samples were observed after hormonal treatment of patients with breast carcinoma (32) . Of these women, 19% had elevated serum levels before treatment, and had varied responses during or after treatment. Of these, 58% were reported to correlate with the clinical outcome. This would tend to suggest a relationship between treatment and serum levels of HER-2/neu, even using only hormonal therapy and not a cytotoxin and/or radiation therapy, which should have a much more pronounced effect not only on the tumor cell, but also on the circulating p105 HER-2/neu.
The normal levels of serum uPA and HER-2/neu we saw compared to the controls suggest that the circulation, not uPA or HER-2/neu, has any bearing on the pathology of cervical cancer in terms of possible induction of invasion and/or metastasis (Tables 1 and 2 ). In the examination of cervical cancer regardless of stage, there was no correlation between uPA and HER-2/neu; this was also seen in the advanced stage of cervical cancer. However the positive correlation found in early disease suggests that uPA may indeed be upregulated by HER-2/neu, as suggested by in vitro experiments (1) . This lack of correlation in the advanced patients may be a reflection of the small number of patients with advanced disease (9) . This might suggest that as cervical cancer is developing during its early stages, upregulation of uPA might be occurring to aid the tumor in its developmental process to invade and spread; a process that was not seen in non-small-cell lung cancer (31) . With the early detection of cervical cancer by cytologic means, this possible relationship of uPA and HER-2/neu can be evaluated further. Most cervical cancers are detected at earlier stages, so this investigation needs expansion into the gynecologic tumors, which are primarily detected at the advanced stage, such as ovarian and endometrial cancer.
These data suggest that cervical cancer may not induce any change in circulating uPA or HER-2/neu. The data also suggest that HER-2/neu may upregulate the uPA in the circulation of patients with early cervical cancer.
